REGN17235
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 08, 2026
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1 trial • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • SF3B1
June 25, 2026
R17235-HM-24125: Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation
(clinicaltrialsregister.eu)
- P1 | N=15 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals Inc.
New P1 trial • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology
1 to 2
Of
2
Go to page
1